Tyagarajan Seshu 4

What Happened Tyagarajan Seshu, Chief Technology Officer of Candel Therapeutics (CADL), was granted a derivative equity award on January 26, 2026 comprising 154,000 shares (reported as acquired at $0.00). The filing shows this is an award/option-type grant (transaction code A) with no cash paid at grant; the reported dollar amount for the acquisition is $0.

Key Details

• Transaction date: 2026-01-26; Form 4 filed 2026-01-28 (two days after the transaction).
• Instrument/price: Derivative award reported as 154,000 shares @ $0.00 (grant of options/rights).
• Vesting: The award vests in forty-eight (48) equal monthly installments beginning January 26, 2026, subject to continued service (footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Filed Jan 28, 2026 (appears to meet the typical 2-business-day Form 4 deadline).

Context This is a compensation-related option/award, not an open-market purchase or sale. Such grants are common for executives and reflect company compensation practices rather than an immediate buy/sell signal—shares will become available only as the award vests and any exercise occurs. No immediate exercise or sale was reported with this grant.